New particle beam therapy targets stubborn liver tumors
NCT ID NCT07252323
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a precise type of radiation called carbon ion radiotherapy for people with liver cancer that remains or comes back after a prior treatment (TARE). About 48 adults will receive this targeted radiation, with doctors tracking how well it shrinks tumors and whether side effects are manageable. The goal is to see if this approach can control the cancer while sparing healthy liver tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carbon ion radiotherapy (a type of radiation therapy using carbon particles)
What this could lead to
If successful, this could offer a new, more precise radiation option for people with liver cancer that hasn't fully responded to initial treatment.
What could go wrong
This is a small, early-phase study (48 participants) with no comparison group. It's unclear if carbon ion therapy is better than other options, and radiation side effects are still possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••